Quốc gia: New Zealand
Ngôn ngữ: Tiếng Anh
Nguồn: Medsafe (Medicines Safety Authority)
Beclometasone dipropionate 50ug;
Teva Pharma (New Zealand) Limited
Beclometasone dipropionate 50 µg
50 mcg/dose
Aerosol inhaler, metered dose
Active: Beclometasone dipropionate 50ug Excipient: Ethanol Norflurane
Aerosol, metered inhaler, actuator, 200 dose units
Prescription
Prescription
Sicor (Societa Italiana Corticosteroidi) Srl
Package - Contents - Shelf Life: Aerosol, metered inhaler, actuator - 200 dose units - 36 months from date of manufacture stored at or below 25°C. do not refrigerate, freeze, puncture or burn.
2003-04-02
NEW ZEALAND CONSUMER MEDICINE INFORMATION BECLAZONE® 50, 100, 250 MICROGRAMS CFC-FREE INHALER BECLOMETASONE DIPROPIONATE 50, 100, OR 250 MICROGRAMS PER METERED DOSE (“PUFF”) Please read this leaflet carefully before you start using Beclazone CFC-Free Inhaler. WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Beclazone CFC-Free Inhaler. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you using Beclazone CFC-Free Inhaler, against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET. YOU MAY NEED TO READ IT AGAIN. WHAT BECLAZONE CFC-FREE INHALER IS USED FOR Beclazone CFC-Free Inhaler is used to help prevent asthma in adults, adolescents and children over 7 years of age. It contains a medicine called beclometasone dipropionate, which belongs to a family of medicines called corticosteroids. Inhaled corticosteroids are not the same as anabolic steroids used by some body-builders and athletes. Your Beclazone CFC-Free Inhaler delivers very small amounts of inhaled corticosteroid straight to your lungs, where it works by reducing inflammation (swelling and irritation) in the small airways. This helps you to breathe easier and helps to prevent asthma attacks. This kind of medicine is known as a ‘Preventer’. It must be used everyday as directed by your doctor even if you have no asthma symptoms. Beclazone CFC-Free Inhaler may take a few days to start to work. Do not stop using your inhaler unless a doctor tells you to. Beclazone CFC-Free Inhaler does not give immediate relief from an asthma attack. Do not use Beclazone CFC-Free Inhaler to relieve wheezing or breathlessness - you may have been given a different kind of inhaler medicine, called a 'Reliever’, for that. Your doctor may have told you to use a Reliever inhaler in addition to your Beclazone C Đọc toàn bộ tài liệu
Version 1.2 1 NEW ZEALAND DATA SHEET 1. PRODUCT NAME BECLAZONE 50 micrograms CFC-Free Inhaler BECLAZONE 100 micrograms CFC-Free Inhaler BECLAZONE 250 micrograms CFC-Free Inhaler (beclometasone dipropionate inhaler, CFC-Free, 50 mcg, 100 mcg and 250 mcg) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each metered dose delivers 50 mcg, 100 mcg or 250 mcg beclometasone dipropionate. Excipient with known effect: ethanol (anhydrous) For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Pressurised inhalation, suspension. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Beclometasone dipropionate provides effective anti-inflammatory action in the lungs and offers preventive background treatment of asthma. Severe asthma requires regular medical assessment as death may occur. Patients with severe asthma have constant symptoms and frequent exacerbations, with limited physical capacity, and PEF values below 60% predicted at baseline with greater than 30% variability, usually not returning entirely to normal after a bronchodilator. These patients will require high dose inhaled (see section 4.2 Dose and method of administration) or oral corticosteroid therapy. Sudden worsening of symptoms may require increased corticosteroid dosage which should be administered under urgent medical supervision. _Adults _ Prophylactic management in: Mild asthma (PEF values greater than 80% predicted at baseline with less than 20% variability): Patients requiring intermittent symptomatic bronchodilator asthma medication on more than an occasional basis. Moderate asthma (PEF values 60-80% predicted at baseline with 20-30% variability): Patients requiring regular asthma medication and patients with unstable or worsening asthma on other prophylactic therapy or bronchodilator alone. Severe asthma (PEF values less than 60% predicted at baseline with greater than 30% variability): Patients with severe chronic asthma. On transfer to high dose inhaled beclometasone dipropionate, many patients who are dependent on systemic corticoster Đọc toàn bộ tài liệu